Adjuvant chemotherapy in Ewing's sarcoma patients

Area of Science:

• Pediatric Oncology
• Skeletal System Neoplasms
• Medical Oncology

Background:

• Ewing's sarcoma is a rare bone cancer primarily affecting children and young adults.
• Historically, treatment relied heavily on local therapies like surgery and radiation.
• Limited data existed on the long-term efficacy of adjuvant chemotherapy in localized Ewing's sarcoma.

Purpose of the Study:

• To evaluate the impact of different treatment protocols on relapse rates in localized Ewing's sarcoma.
• To compare outcomes between local therapy alone and combined modality treatment including adjuvant chemotherapy.
• To assess the effectiveness of adjuvant chemotherapy in preventing recurrence after radiotherapy.

Main Methods:

• Retrospective analysis of 60 patients with clinically localized Ewing's sarcoma treated between 1965 and 1978.
• Group 1 (1965-1971): 18 patients received primarily local therapy.
• Group 2 (1971-1978): 42 patients received radiotherapy followed by adjuvant chemotherapy (two different schedules).

Main Results:

• Patients treated with local therapy alone had a high relapse rate (17/18, 94%) with a median relapse time of 6 months.
• In the adjuvant chemotherapy group, 25/42 (59%) patients are currently alive and relapse-free.
• Follow-up duration for the chemotherapy group ranged from 20 to 101 months.

Conclusions:

• Adjuvant chemotherapy significantly reduces relapse rates in localized Ewing's sarcoma compared to local therapy alone.
• Combined modality treatment, including radiotherapy and adjuvant chemotherapy, offers a more effective strategy for disease control.
• These findings underscore the importance of systemic therapy in managing localized Ewing's sarcoma to improve patient survival and prevent recurrence.